Novo Nordisk Misled USPTO, Federal Circuit Rules
Novo Nordisk misled the patent office when it applied for a patent for a human growth hormone, the Federal Circuit ruled in a decision that will derail the company's bid to...To view the full article, register now.
Already a subscriber? Click here to view full article